In an open-label, pharmacokinetic drug interaction study of Pasurta and a combined oral contraceptive in healthy female subjects, erenumab (140 mg subcutaneous [SC], single- dose) did not affect the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate.
In a randomized, double-blind, placebo-controlled study in healthy volunteers, concomitant administration of erenumab (140 mg intravenous [IV], single-dose) with sumatriptan had no effect on resting blood pressure compared with sumatriptan alone. Pasurta had no effect on the pharmacokinetics of sumatriptan.
Erenumab is not metabolized by cytochrome P450 enzymes and is unlikely to cause marked changes in pro-inflammatory cytokines that may impact cytochrome P450 enzyme expression or activity. As a result, interactions with concomitant medications that are substrates, inducers, or inhibitors of cytochrome P450 enzymes are unlikely.
Interference with laboratory and diagnostic tests: Interference of Pasurta with laboratory and/or diagnostic tests has not been studied.